The epidermal growth factor receptor (EGFR) is activated by a variety of ligands including EGF and transforming growth factor-alpha (TGFa), whereas no ligand for the homologous ErbB2 oncoprotein has yet been identi®ed. Here we use both an ErbB2 phosphoantibody (aPY 1222 ) and an activation-speci®c EGFR antibody to show that low concentrations of EGF induce more ecient tyrosine phosphorylation of ErbB2 in A431 cells than does equimolar TGFa, while EGFR is more potently activated by TGFa. Co-precipitation studies con®rm that heterodimerization of activated EGFR and transphosphorylated ErbB2 is readily induced by EGF but not TGFa. EGFR downregulation is also more eciently induced by EGF, suggesting that liganddependent modi®cation of ErbB2 may be required to terminate EGFR signalling in cells expressing both receptor types. These ®ndings indicate that EGF and TGFa dier in their abilities to induce tyrosine phosphorylation and heterodimerization of ErbB2, and raise the possibility that ErbB2 exerts its oncogenic eect in part by impairing TGFa-dependent EGFR downregulation.
Introduction
Transforming growth factor-alpha (TGFa) is one of several ligands which activate the epidermal growth factor receptor (EGFR) (Derynck, 1988) . TGFa is more widely expressed in normal adult tissues than is EGF, and the two ligands have comparable EGFR binding anities (Lee et al., 1995) . Despite this, TGFa may exert greater mitogenic potency than EGF in vitro (Gabelman and Emerman, 1992) and in vivo (Gan et al., 1987) , suggesting that TGFa functions as an EGFR superagonist' in some cells and tissues. Moreover, unlike EGF, TGFa has been widely implicated in the pathogenesis of autocrine growth loops in cancer cells and tumours (Mellon et al., 1996; Muller et al., 1996; Stromberg et al., 1992) . These functional distinctions between EGF and TGFa have led to a search for physical properties explaining their presumably distinct biological roles.
Just as curious as this abundance of EGFR ligands has been the apparent lack of a homodimerizing ligand for the structurally related receptor ErbB2 (neu/ HER2; Stern et al., 1986) . ErbB2 avidly heterodimerizes with all type I receptor tyrosine kinases, and does so with EGFR in response to EGF (Qian et al, 1994; Spivak-Kroizman et al., 1992) which also induces ErbB2 transphosphorylation (Stern and Kamps, 1988) . In earlier work we developed phosphorylation-speci®c antibodies recognizing different functional states of ErbB2 (Epstein et al., 1992; Ouyang et al., 1996) ; one of these, aPY 1248 , recognizes a kinase-active ErbB2 isoform (Epstein et al., 1992) which is predicted to associate with phospholipase C-g (Songyang et al., 1993) . The signalling signi®cance of the immediately N-terminal Y 1222 phosphorylation site (Hazan et al., 1990) remains unknown , though homology with EGFR suggests that the SH2 domain of Shc (Okabayashi et al., 1994) may bind to this sequence. Since Shc transforms cells when phosphorylated by ErbB2 (Xie et al., 1995) , recruitment of this protein by Y 1222 phosphorylation could prove a critical signalling event. In this report we use a novel phosphoantibody raised against the Y 1222 site to show that EGF and TGFa exert dierential eects on EGFR hetero-oligomerization and downregulation.
Results

The aPY
1222 antibody speci®cally detects ErbB2 in ligand-stimulated cells
The aPY 1222 polyclonal antibody was prepared and validated as described in detail for other ErbB2 phosphoantibodies (Epstein et al., 1992; Ouyang et al., 1996) . To determine the receptor-speci®city and ligand-inducibility of aPY 1222 , control and EGF-treated A431 cell lysates were immunoblotted in parallel using either aPY 1222 , antiphosphotyrosine (aPY), or antibodies to ErbB2 (pAb-1, Triton). Figure 1 (upper panel) shows that EGF induces prominent tyrosine phosphorylation of EGFR as indicated by the appearance of a 170 kDa band (clearly lower than the 190 kDa ErbB2 band ± B2 ± seen at left) on aPY immunoblotting. In contrast, immunoblotting with aPY 1222 (1222, lower panel) reveals a major EGF-inducible 190 kDa band which migrates more slowly on SDS ± PAGE than does the EGFR (B1; at left) itself. Given the high expression of EGFR in A431 cells (Ullrich et al., 1984) , these data indicate that aPY 1222 speci®cally recognizes ErbB2 in EGF-treated samples.
A431 cells provide a sensitive ligand-inducible experimental system for the detection of aPY 1222 immunoreactivity A431 human squamous carcinoma cells are characterized by an uncommon expression pattern of type I receptors, with extremely abundant EGFR (Ullrich et al., 1984) , modest levels of ErbB2 and ErbB3 (Solto et al., 1994) , and minimal ErbB4 (Plowman et al., 1993) . Moreover, we have noted that prolonged passage of this cell line is associated with gradual ErbB2 upregulation (Huang et al, unpublished data) . In contrast, G8/DHFR is a stably-transfected NIH3T3 cell line expressing a vast excess of ErbB2 (Stern et al., 1986) , much of which is constitutively activated in serum-starved cells (Epstein et al., 1990) ; at least some of this activated ErbB2 receptor subset is heterooligomerized with the heregulin receptor ErbB3 (Huang et al, submitted) . EGF treatment of A431 cells induces profound EGFR activation (Carpentier et al., 1987; Kawamoto et al., 1983) which is associated with readily detectable enhancement of aPY 1222 immunoreactivity, perhaps indicating a net reduction in ErbB2 heterodimerization or active induction of ErbB2 dephosphorylation. We conclude that cells which grossly overexpress ErbB2 relative to liganded growth factor receptors do not necessarily represent optimal in vitro systems for the sensitive detection of heterologous ErbB2 phosphorylation events, whereas the unusual receptor stoichiometry of A431 cells may provide a uniquely informative assay for monitoring post-translational modi®cation of ErbB2 in response to EGF.
EGF induces ErbB2 tyrosine phosphorylation more eciently than TGFa
To compare the eects of EGF and TGFa on A431 cells, low concentrations of these ligands were ®rst used to treat cells prior to immunoblotting with either aPY 1222 or aPY. Figure 3 shows that EGF treatment more potently enhances immunorecognition of ErbB2 by aPY 1222 than does equimolar TGFa ± this dierence declines as ligand concentrations rise above 6 nM (Gulliford et al., unpublished data). In contrast, tyrosine phosphorylation of a 170 kDa band is more readily detected by aPY in TGFa-than in EGFstimulated cells (Figure 3 ). This divergence of liganddependent aPY and aPY 1222 immunoreactivity con®rms that aPY 1222 binding does not simply parallel increased cellular phosphotyrosine. In addition, we note that these data tend to exclude the possibility that dierential induction of aPY 1222 immunoreactivity re¯ects inadvertent dierences in quality or concentration of the ligands used.
TGFa causes more potent EGFR activation than does equimolar EGF in cells co-expressing EGFR and ErbB2
In view of the greater potency of TGFa in inducing aPY binding to a 170 kDa band ( Figure 3 , right panels), we used an activation-speci®c EGFR monoclonal antibody recognizing a conformational epitope (Campos-Gonzalez and Glenney, 1991) to elucidate further the relative eects of EGF and TGFa on EGFR and ErbB2. Control experiments con®rmed the activation-speci®city of the EGFR antibody batch immunoblotting. Furthermore, we note that this reciprocal pattern is theoretically consistent with a stoichiometric dierence in ligand-dependent receptor association.
EGF selectively induces the hetero-oligomerization of activated EGFR and transphosphorylated ErbB2
To determine whether the foregoing ligand-dependent dierences in ErbB2 transphosphorylation were associated with variations in heterodimer formation, coimmunoprecipitation studies were undertaken. A striking enhancement of EGFR association with aPY 1222 -bound ErbB2 is evident following EGF, but not TGFa, treatment (Figure 5a ). Since this dierence could re¯ect a greater amount of ErbB2 immunoprecipitated from EGF-treated cells, rather than a primary dierence in receptor heterodimerization, ligand-treated samples were then immunoprecipitated using the activationspeci®c EGFR antibody. Figure 5b shows that ± despite the greater EGFR-activating potency of TGFa ( Figures  3 and 4) and the immunoprecipitation in this experiment of comparable EGFR amounts following treatment with the two ligands (Figure 5b , lower panel) ± transphosphorylated ErbB2 associates predominantly with activated EGFR in EGF-treated samples (Figure 5b , upper panel). We conclude that EGF preferentially induces formation of EGFR/ErbB2 hetero-oligomers, and speculate by default that TGFa may primarily activate EGFR by homo-oligomerization.
EGFR downregulation is more readily induced by EGF than by TGFa
To assess the eect of dierential ErbB2 heterooligomerization on EGFR signalling, we then determined the kinetics of EGFR downregulation following prolonged A431 cell exposure to EGF or TGFa. Figure 6 shows that EGF causes detectable EGFR downregulation within 4 h, and marked downregulation within 24 ± 48 h. In contrast, EGFR levels in TGFa-treated samples¯uctuate but remain high over this same period. The reduced ability of TGFa to induce ErbB2 transphosphorylation and heterodimerization thus appears associated with less ecient -phosphorylated ErbB2. Cells were stimulated for 5 mins with either EGF (E, 6 nM) or TGFa (T, 6 nM) prior to lysis and immunoprecipitation using an activation-speci®c EGFR monoclonal antibody (EGFR*). Subsequent immunoblotting was carried out using either aPY 
Discussion
The central ®nding of this study is that two`dedicated' EGFR ligands, EGF and TGFa, dier in their propensity to induce heterologous interaction with ErbB2. This dierence relates to the more potent induction by EGF of hetero-oligomerization between ligand-activated EGFR and a functional ErbB2 subset distinguished by the aPY 1222 antibody. Hence, consistent with earlier models based on binding studies (Gabelman and Emerman, 1992; Gadella and Jovin, 1995; Kawamoto et al., 1983) , a plausible speculation is that EGFR homo-oligomers constitute high-anity TGFa binding sites whereas EGFR/ErbB-2 heterooligomers provide high-anity EGF binding sites. Moreover, we note that this model could explain earlier reports of divergent concentration-dependent response ranges for EGFR activation by EGF and TGFa (Gabelman and Emerman, 1992) .
The relative inability of TGFa to mimic the heterooligomerizing potency of EGF is associated with impaired ligand-dependent EGFR downregulation (Figure 6 ), suggesting that heterologous receptor interaction with ErbB2 may be a prerequisite for physiological termination of EGFR signalling in cells co-expressing ErbB2. This possibility is consistent with recent work showing that EGF-dependent ErbB2 downregulation is dependent on ErbB2 tyrosine phosphorylation (Worthylake and Wiley, 1997) . Moreover, the slow EGFR downregulation kinetics in ErbB2-expressing cells in these studies diers from that seen in ErbB2-naõÈ ve EGFR-transfected 3T3 cells which undergo receptor downregulation to undetectable levels within 2 h of ligand treatment (Huang et al., unpublished data) . This suggests in turn that the neoplastic signi®cance of ErbB2 overexpression may relate at least in part to the eect of this phenotype on EGFR signalling kinetics, though the mechanism by which this eect is mediated remains to be elucidated.
Several methodologic variables complicate the type of analysis presented here, and may account for apparent inconsistencies between published comparisons of EGF and TGFa behaviour. One such factor already mentioned is the choice of cell line; substantial variations in receptor stoichiometry characterize dierent cell lines, leading to wholly distinct patterns of signalling response to ligand (Figure 2 ). This consideration raises particular interpretational doubts relating to studies using cell lines which have been engineered to overexpress ErbB2, since receptor overexpression ipso facto may predispose to oligomerization (Di Fiore et al., 1987; Di Marco et al., 1990; Hudziak et al., 1987; Taylor et al., 1995) . Conversely, a disadvantage of using the A431 cell line is that it is dicult to detect the expected ligand-inducible association with ErbB2 when using conventional EGFR antibodies for immunoprecipitation, re¯ecting the vast excess of EGFR (most of which remains unactivated even at ligand concentrations as high as 20 nM; Gulliford et al., unpublished data) over ErbB2 expression in these cells.
A second potential variable relates to experimental ligand concentrations. Very high ligand concentrations may lead to a variety of confounding eects, including nonspeci®c receptor interactions, saturation of downstream feedback pathways, signal nonlinearity, secondary adaptational responses, or cell toxicity. Others have shown that TGFa can induce EGFR-dependent ErbB2 hetero-oligomerisation (Riese et al., 1996) and transphosphorylation (Beerli and Hynes, 1996) in transfected cell lines, for example, but interpretation of these observations is complicated by the use of pharmacologic ligand concentrations. The duration of experimental ligand exposure is yet another variable, and one which casts generalizable doubts over the relevance of short-term experiments to the in vivo microenvironment. For unlike brief treatments, prolonged (e.g. 1 ± 2 weeks) stimulation with low concentrations of a single ligand can lead to massive shifts in cell-surface expression levels of multiple receptor types (Gulliford et al., unpublished data); such shifts eectively create a distinct experimental system which may be more pertinent to the smooth regulatory milieu of tissues in living organisms.
Finally, many commercial antibodies which purport to detect a given protein in a nonselective manner may in fact recognize functional subsets, thus inadvertently biasing experimental outcomes. For example, our preliminary attempts to con®rm EGF-dependent EGFR heterodimerization using an immunoprecipitating ErbB2 antibody ± which happens to be dephosphorylation-speci®c (Epstein, 1995) ± may well have been confounded by transphosphorylation of ErbB2 in this context. The rational use of phosphorylation-and/ or activation-speci®c antibodies may thus represent a sensitive strategy for analysing the mechanics of hetero-oligomer formation; indeed, though not proven here, our ®ndings raise the possibility that receptor transphosphorylation may actually imply heterooligomerization.
In conclusion, our ®ndings indicate that TGF can selectively activate EGFR in the absence of ErbB2 modi®cation, and that this is associated with less ecient EGFR downregulation in an ErbB2-coexpressing cell line. Relevant to this, a synergistic tumorpromoting eect of TGFa and ErbB2 has been reported in bigenic mice (Muller et al., 1996) . We submit that this apparent oncogenic synergy could involve a reduced ability of TGFa to terminate EGFR signalling, and speculate that this mechanism may in turn contribute to the clonal outgrowth of human tumours simultaneously overexpressing both TGFa and ErbB2.
Materials and methods
Cells, growth factors and antibodies
A431 cells were obtained from the American Type Culture Collection, and the G8/DHFR cell line was a kind gift of Robert Weinberg. Synthetic forms of the human growth factors EGF and TGFa were purchased from Sigma. Monoclonal antiphosphotyrosine (4G10; aPY) was a kind gift of Brian Druker and Tom Roberts. Monoclonal EGFR antibody (clone F4) was obtained from Sigma, and antibody to activated EGF receptor (Campos-Gonzalez and Glenney, 1991) from Zymed (clone ZO26; EGFR*). A commercial polyclonal ErbB2 antibody (pAb-1; Triton, CA) was used to detect total ErbB2 expression as previously described (Epstein, 1995; Epstein et al., 1990) . Stock cultures were routinely grown in a 5% CO 2 incubator in RPMI (A431) or DMEM (G8/DHFR) as described previously (Ouyang et al., 1996) .
Development of phosphotyrosine-speci®c aPY 1222 ErbB2 antibody
Using an identical approach as detailed earlier for the aPY 1248 (Epstein et al., 1992) and aPT 686 (Ouyang et al., 1996) ErbB2 phosphoantibodies, an ErbB2-speci®c polyclonal antiserum was raised against the Y 1222 -containing ErbB2 C-terminal peptide sequence PAFDNLYYWDQDP (Hazan et al., 1990) . Phosphopeptide synthesis and antibody validation were carried out as described (Epstein et al., 1992; Ouyang et al., 1996) . Optimal speci®city was determined for each antibody batch using lysates of control, ligand-stimulated and vanadate-treated A431 and G8/DHFR cells, and by preabsorbing antibodies with either the phosphopeptide or a corresponding dephosphopeptide as described previously (Epstein, 1995; Ouyang et al., 1996) . The antibody was used at 1 : 5000 dilution for immunoblotting and at 1 : 100 for immunoprecipitation.
Immunoblotting and immunoprecipitation
Cell protein lysis was carried out by washing monolayer cultures twice with ice-cold PBS then adding lysis buer (10 mM Na 2 HPO 4 .7H 2 O, 10 mM NaH 2 PO 4 .H 2 O, 150 mM NaCl, 1% Nonidet P-40 (v/v), 10% glycerol (v/v), 50 mM sodium¯uoride, 10 mM sodium pyrophosphate) plus tyrosine phosphatase and protease inhibitors (sodium orthovanadate 1 mM, leupeptin 40 mM, aprotinin 10 mg/ ml, phenylmethylsulfonyl¯uoride 1 mM) for 15 min at 48C with gentle rocking. Following centrifugation, lysates for immunoblotting and immunoprecipitation were handled as described (Epstein et al., 1990) , and ECL development carried out according to standard protocols (Ouyang et al., 1996) . Densitometric band quanti®cation was undertaken using a BioRad Molecular Imager and Molecular Analyst software.
